Innovent Announces the Results of P-II Study for Mazdutide (IBI362) in Chinese Patients with Overweight or Obesity
Shots:
- The P-II study evaluating Mazdutide (3 mg, 4.5 mg & 6 mg) vs PBO at 24 wks. in Chinese patients with overweight or obesity demonstrated a mean change from baseline in body weight were −6.7%, −10.4%, & −11.3% vs −1.0%
- The PBO-adjusted mean change from baseline in body weight was −7.7%, −11.4%, and −12.3%. The proportion of patients with body weight loss of ≥5% were 58.1%, 82.5% & 80.3% vs 4.8%. Additionally, the proportion of patients with body weight loss of ≥10% were 19.4%, 49.2% & 50.8% vs 0%
- Mazdutide, a dual agonist for GLP-1R and GCGR is an analogue of OXM, boosts insulin secretion, lowers blood glucose, and reduces body weight
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
